MVA-Spike encoding the A subunit of dmLT safely enhances systemic and mucosal immune responses
Our findings demonstrate that the A subunit of dmLT is a potent in-built adjuvant when expressed by MVA. It induces systemic and mucosal immune enhancement comparable to the full toxin mutant without any toxicity. Combining the strong immunogenic profile of MVA with the mucosal immune-modulating properties of the A subunit of dmLT represents a highly effective new vaccine platform.
Authors
- Stephan Rambichler
- Clémentine Durand
- Barbara Bathke
- André Riedl
- Florian Brod (ORCID: https://orcid.org/0000-0003-4779-3733)
- Mark Suter
- Jürgen Hausmann
- Ronny Kassub
- Kerstin Lämmermann
- Alexander Heiseke
- Maria Hinterberger (ORCID: https://orcid.org/0000-0003-2672-9134)
- Markus Feigl
- José Medina-Echeverz
- Hubertus Hochrein
- Paul Chaplin
- Andrea Koppius
- Rodrigo Carrasco-León
- Živa Fras
Institutions
- GlaxoSmithKline (Germany) (DE)
- Bavarian Nordic (United States) (US)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-02-05
- DOI
- https://doi.org/10.3389/fimmu.2026.1771410
- Primary Topic
- vaccines and immunoinformatics approaches
- Type
- article
- Field-Weighted Citation Impact
- 0.00